Cholinergic mechanisms in an organic dust model simulating an acute exacerbation in patients with COPD

Lena Palmberg*
Britt-Marie Sundblad*
Jie Ji
Jakob Karén
Kjell Larsson

Work Environment Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

*These authors contributed equally to this work

Background: Exposure in a pig barn induces airway inflammation that has similarities with the response observed in acute exacerbations in COPD.

Methods: A total of 15 smokers with COPD and 15 healthy non-smokers were exposed for 2 hours in a pig barn (in vivo exposure). Symptoms were assessed, lung function measured, and blood and sputum samples taken before and after exposure. Blood neutrophils were isolated and stimulated ex vivo with dust from a pig barn and acetylcholine, and inflammatory markers were analyzed.

Results: In vivo exposure caused more symptoms and greater lung function fall in COPD patients than in controls. Baseline concentrations of MMP9, TIMP1, IL6, CXCL8, in sputum and neutrophil blood count were higher in COPD patients than in controls. In vivo exposure increased MMP9, TIMP1, IL6, CXCL8, TNFα, and LTB4 in sputum and MMP9 and IL6 in blood, with no difference between the groups, and serum CRP increased more in COPD subjects. Expression of choline acetyltransferase and acetylcholinesterase on sputum and blood cells was similar in the groups and uninfluenced by in vivo exposure. Dust exposure ex vivo increased choline acetyltransferase expression in neutrophils, but the dust and acetylcholine response did not differ between the groups before and after in vivo exposure.

Conclusion: COPD patients exposed in a pig barn experience symptoms similar to those in acute exacerbations and lung function deterioration that is unrelated to bronchial responsiveness. Cholinergic mechanisms are involved in the inflammatory response to dust, with no difference between COPD and non-smokers.

Keywords: organic dust, airway inflammation, chronic obstructive pulmonary disease, COPD, pig barn

Introduction

In healthy subjects, a few hours' exposure in a pig barn induces a substantial increase in bronchial responsiveness to methacholine, an intense airway inflammation with a cellular dominance of neutrophils, and a systemic reaction reflected by increased body temperature and increased levels of circulating IL6 and acute-phase proteins. In a number of studies, dust collected in pig barns has been shown to have strong pro-inflammatory properties when bronchial epithelial cells, lymphocytes, alveolar macrophages, monocytes, and neutrophils have been stimulated ex vivo. Bioaerosols in agricultural settings, including pig farming, have been recognized as risk factors for development of airway diseases, such as chronic bronchitis and COPD.

Exacerbations in COPD are triggered by airway bacterial and viral infections, but other factors, such as air pollution, may also cause exacerbations. Living close to
livestock farms increases respiratory symptoms in subjects with COPD, suggesting an increased risk of exacerbations, as exacerbations are associated with increased symptoms, more intense airway inflammation, and systemic engagement. Characteristic exacerbation features are more cough, phlegm, more severe dyspnea, and increased numbers of neutrophils and pro-inflammatory cytokines, eg, IL6, IL1β, and TNFα, and chemokines eg, CXCL8 (IL8) in the airways and systemic circulation.

Ex vivo whole-blood stimulation with dust from a pig barn and its components demonstrate an increased responsiveness with augmentation of cytokine/chemokine release in COPD subjects compared with healthy volunteers. These data may suggest that circulating blood cells in COPD subjects may be primed to respond more to microbial/inflammatory insult. It is known that anticholinergic drugs prevent exacerbations induced by pro-inflammatory stimuli, such as microorganisms, in COPD, supporting the assumption that cholinergic mechanisms are of importance for the inflammatory response. Pro-inflammatory stimuli may elicit cholinergic response by direct interaction with or regulation of muscarinic receptors, by increased expression of choline acetyltransferase (ChAT) and/or by decreased expression of acetylcholinesterase (AChE).

The inflammatory response to acute exposure in a pig barn in healthy subjects has similarities with inflammatory features of acute exacerbations in COPD. Our hypothesis was that clinical, inflammatory, and physiological responses to acute exposure to organic material in a pig barn are stronger in COPD than in healthy non-smokers. Furthermore, we hypothesized that cholinergic responses may be augmented in COPD compared with healthy non-smokers. Therefore, symptoms, airway and systemic inflammation and lung function were assessed before and after exposure in a pig barn and a bronchial methacholine challenge in subjects with COPD and healthy non-smokers. In addition, blood neutrophils were collected before and after exposure and stimulated with dust (collected in the barn) and acetylcholine, and responses to different drugs interacting with cholinergic mechanisms were studied ex vivo.

Methods

Subjects

Fifteen smokers (recruited from the local primary care and by advertisements) with mild or moderate COPD (FEV1 >50% of predicted normal value, ie, stage 1 and 2 according to GOLD)12 and 15 healthy non-smokers matched by age and sex (controls) were included in the study. None of the subjects in the COPD or control group had a history of atopy, asthma, or allergy (confirmed with negative skin-prick tests to a panel of 12 common allergens) or any other chronic diseases. None had suffered from any respiratory tract infection during the last 2 weeks prior to the study. Seven subjects in the COPD group were on pharmacological COPD treatment, five a combination of inhaled steroids and a long-acting β2-agonist, three inhaled tiotropium, one indacaterol, and one salbutamol on demand. No medication was allowed for 48 hours prior to exposure. All subjects gave written informed consent, and the study was approved by the Ethics Committee, Stockholm, Sweden (protocol 2010/2:8).

Study design

All participants visited the laboratory on three occasions ≥1 week apart. At each visit, lung function was measured, induced sputum performed, and blood samples taken. At the first visit, baseline measurements were performed. At the other two visits, measurements were conducted after a bronchial methacholine challenge or after exposure in a pig barn. Medication with short-acting β2-agonists was not allowed for 8 hours and long-acting β2-agonists and anticholinergics for 48 hours prior to each visit.

Subjects from both groups were exposed for 2 hours in the pig barn assisting the farmer who was weighing pigs. Measurements of exposure levels were carried out on each occasion. Spirometry was performed at the first visit, at the visit in connection with the methacholine bronchial challenge, and 7 hours after commencing exposure in the pig barn. Peak expiratory flow (PEF), symptoms, and body temperature were recorded before and 2, 3, and 5 hours after exposure. For study design, see Figure 1.

Throughout the manuscript, “in vivo exposure” refers to 2 hours’ exposure in the pig barn. “Ex vivo exposure” refers to stimulation (dust, acetylcholine, and dust + acetylcholine) and drug intervention of isolated blood neutrophils collected from the participants before and after in vivo exposure.

Exposure measurements

IOM filter cassettes (25 mm; SKC Ltd, Blandford Forum, UK) and plastic cyclones (25 mm; Casella Solutions, London, UK) were used to monitor inhalable and respirable dust levels, respectively. The samplers were placed in the breathing zone on two subjects at each exposure. The cassettes were equipped with Teflon filters (1 μm; Millipore, Sundbyberg, Sweden).

Symptoms

The COPD Assessment Test was completed at visit 1 and before in vivo exposure. Symptoms (headache, chills, fatigue, muscle pain, nausea, sneezing, nasal congestion,
nasal secretion, cough, chest tightness, shortness of breath, and wheezing) were assessed on a VAS (0–100 mm) before and immediately after conclusion of the methacholine challenge and immediately after and at the time of maximal experienced symptoms after in vivo exposure. The subjects were requested to put a cross on a scale where 0 indicated no symptoms and 100 indicated unbearable symptoms. All participants were contacted by phone 24 hours after exposure and asked about symptoms experienced.

Lung function and bronchial provocation

VC, FVC, and FEV\textsubscript{1} were measured using a wedge spirometer (Vitalograph, Buckingham, UK) according to American Thoracic Society criteria.\textsuperscript{19} PEF was measured with a mini-Wright peak-flow meter (Clement Clarke International Ltd, Harlow, UK). Local lung function reference values were used.\textsuperscript{19,20} Bronchial provocation to methacholine was performed as previously described.\textsuperscript{21} Inhalation of the diluent was followed by inhalation of doubling concentrations of methacholine up to 32 mg/mL, starting at 0.5 mg/mL. The result was expressed as the cumulative dose causing a 20% decrease in FEV\textsubscript{1} (PD\textsubscript{20} FEV\textsubscript{1}).

Sputum induction and processing

Sputum induction and processing were performed as previously described,\textsuperscript{22} with minor modifications. After inhalation of salbutamol (0.4 mg) sputum was induced by inhalation of saline in increasing concentrations (0.9%, 3%, 4%, and 5%) using an ultrasonic nebulizer (UltraNeb 2000; Drive DeVilbiss Healthcare, Mannheim, Germany) with an output of 3 mg/mL. Each concentration was inhaled for 6–7 minutes, followed by FEV\textsubscript{1} measurement. Subjects were asked to blow their nose and rinse their mouth with water before the induction and before expectorating sputum by deep coughing. The sample was considered adequate macroscopically if it appeared to be free from saliva and had a weight ≥2,000 mg.

Sputum color and weight were determined and an equal volume of 0.1% dithiothreitol added to the whole sputum sample and rocked for 15–25 minutes in a 37°C water bath and thereafter passed through a filter. The sample was centrifuged (10 minutes at 280 g) and the supernatant stored in aliquots at −70°C until analysis. Cell pellets were resuspended in 2 mL PBS, and total cell count and viability test with Trypan blue was performed.

Serum/blood

Peripheral blood was collected in supplement-free tubes and EDTA Vacutainer\textsuperscript{®} tubes (BD Biosciences, San Jose, CA, USA). Samples in supplement-free tubes were left 60 minutes to clot and then centrifuged twice at 3,000 rpm for 10 minutes. The serum obtained was then aliquoted and stored in −70°C until analyses. Samples in EDTA Vacutainer tubes were used for flow-cytometry analysis.
Ex vivo stimulation of blood cells
Isolation of blood neutrophils
Whole blood was mixed with equal volumes of PBS (Thermo Fisher Scientific, Waltham, MA, USA)–dextran 2% (Sigma-Aldrich Co., St Louis, MO, USA) and left for sedimentation for 30–40 minutes. Leukocyte-containing dextran blood was put gently on top of an equal volume of Lymphoprep (STEMCELL Technologies, Vancouver, BC, Canada) and then centrifuged at 600 × g for 25 minutes without using brake. The cell pellet was then resuspended in PBS, washed and lysed in deionized water, washed, and finally resuspended in RPMI (Sigma-Aldrich Co.) supplemented with 1% L-glutamine, 10% heat-inactivated FBS, and penicillin–streptomycin antibiotics (BioWhittaker™, Lonza, Basel, Switzerland). Cell concentration was calculated in a Bürker chamber.

Stimulation of peripheral blood neutrophils
Cells (500,000 per well) were seeded in 24-well plates (Nunc A/S, Roskilde, Denmark). Cells were stimulated with organic dust collected from pig-barn shelves and window ledges about 1.2 m above the floor (1 μg/mL), acetylcholine (100 μM), or a combination of dust and acetylcholine, which were added to the wells. To these, stimuli of tiotropium (3, 30, 100 nM; Santa Cruz Biotechnology Inc.), neostigmine (200 μM; Sigma-Aldrich Co., St Louis, MO, USA), solifenacin (200 nM), acetylcholine (100 μM), or pirenzepine (10 μM; Sigma-Aldrich Co.) was added. After incubation at 37°C in 5% CO2 for 16 hours, cells and cell media were centrifuged at 400 × g for 10 minutes and cells and supernatants collected for further analyses.

Blood-cell distribution
To determine absolute cell numbers in peripheral blood, Trucount tubes containing a specific number of beads were used. Whole blood and a four-color antibody mixture (CD3FITC/CD8PE/CD45PerCp/CD4APC; BD Biosciences, San Jose, CA, USA) were added to a Trucount tube (BD Biosciences, San Jose, CA, USA) and incubated for 20°C-22°C for 15 minutes. To lyse red blood cells, 450 μL Pharm Lyse™ (BD Biosciences) was added and an additional 10-minute incubation in the dark at 20°C-22°C performed. All samples were then analyzed on a FACSCalibur™ (BD Biosciences) and tubes incubated for 30 minutes in the dark at RT. Cells were then washed with 500 μL Cytoperm/Cytofix wash and centrifuged at 400 × g for 5 minutes, before the secondary antibody FITC–antimouse (Abcam) was added and tubes incubated for 30 minutes in the dark at RT. Cells were then resuspended in PBS and analyzed on the FACSCalibur. The other two tubes were analyzed for ChAT and AChE.

Stimulated neutrophils, 200 μL blood, and 500 μL sputum were permeabilized by addition of Cytoperm/Cytofix (BD) and incubated for 20 minutes at RT in the dark. Cells were centrifuged at 400 × g for 5 minutes, before 500 μL of Cytoperm/Cytofix wash was added and samples incubated for 10 minutes. Cells were again centrifuged at 400 × g for 5 minutes, before primary antibody ChAT (Abcam) or AChE (Abcam) was added and tubes incubated for 30 minutes in the dark at RT. Cells were then washed with 500 μL Cytoperm/Cytofix wash and centrifuged at 400 × g for 5 minutes, before the secondary antibody FITC–antimouse (Abcam) was added. Samples were incubated an additional 30 minutes in the dark at RT before analysis with the FACSCalibur.

ELISA
MMP9, TIMP1, TGFβ, and LTB4 were measured using a DuoSet ELISA MMP9 kit, DuoSet ELISA TIMP1 kit, DuoSet ELISA TGFβ kit (R&D Systems Inc., Minneapolis, MN, USA), and LTB4 EIA kit (Cayman Chemical, Ann Arbor, MI, USA). The lower detection limit for MMP9, TIMP1, and TGFβ was 31.125 pg/mL and for LTB4, 3.91 pg/mL. Serum IL6, TNFα, and CRP were measured using an HS QuantiKine ELISA IL6 kit, HS QuantiKine ELISA TNFα kit (R&D Systems Inc.), and high-sensitivity CRP test with detection limits of 0.2 pg/mL, 0.5 pg/mL, and 0.2 ng/mL, respectively. All analyses were performed in accordance with the manufacturer’s instructions. Measurement of IL6 and CXCL8 in sputum was performed using an in-house ELISA with detection limits of 3 pg/mL and 50 pg/mL, respectively.

Luminex
CXCL10, CXCL8, and TNFα in the supernatant of ex vivo stimulated neutrophils were determined based on Luminex technology. A Bio-Plex Pro™ reagent kit III (Bio-Rad Laboratories (PE; BD Biosciences), CXCR3-FITC (BD Biosciences), CD25–allophycocyanin (APC; BD Biosciences), or CD69–FITC (BD Biosciences) antibodies and incubated in the dark at room temperature (RT) for 30 minutes. Then, 450 μL lysis solution (BD Biosciences) was added to each tube and incubated for 10 minutes, before samples were analyzed with the FACSCalibur.

Stimulated blood neutrophils were collected after 16 hours of stimulation by centrifugation at 300 × g for 10 minutes. The cell pellet was divided into three tubes. CXCR1–FITC and CXCR2–PE antibodies were added to one tube and incubated in the dark at RT for 20 minutes, before samples were analyzed on the FACSCalibur. The other two tubes were analyzed for ChAT and AChE.

Stimulated neutrophils, 200 μL blood, and 500 μL sputum were permeabilized by addition of Cytoperm/Cytofix (BD) and incubated for 20 minutes at RT in the dark. Cells were centrifuged at 400 × g for 5 minutes, before 500 μL of Cytoperm/Cytofix wash was added and samples incubated for 10 minutes. Cells were again centrifuged at 400 × g for 5 minutes, before primary antibody ChAT (Abcam) or AChE (Abcam) was added and tubes incubated for 30 minutes in the dark at RT. Cells were then washed with 500 μL Cytoperm/Cytofix wash and centrifuged at 400 × g for 5 minutes, before the secondary antibody FITC–antimouse (Abcam) was added. Samples were incubated an additional 30 minutes in the dark at RT before analysis with the FACSCalibur.
Inc., Hercules, CA, USA) was used in accordance with the manufacturer’s instructions. Data were analyzed with Bio-Plex Manager™ software (Bio-Rad Laboratories Inc.). For all duplicated samples, intra-assay variation <15% was accepted. Detection limits of CXCL10 (IP10), CXCL8, and TNFα were 0.52, 0.47, and 1.29 pg/mL, respectively.

**Statistical analyses**

Results are presented as median (25th–75th percentiles) and mean (95% CI) for lung function, mean (SEM), or mean (range). Results from in vivo exposure (pig barn and methacholine) were compared by mean of Wilcoxon signed-rank tests within groups, Mann–Whitney U tests between groups (blood and sputum analyses), or paired and unpaired t-tests (lung function, symptoms).

Ex vivo results were compared by mean of ANOVA for repeated measurements, followed by dependent or independent t-tests post hoc for three or more comparisons. For pairwise comparisons, Wilcoxon signed-rank test was used within groups and Mann–Whitney U test between groups. P<0.05 was considered statistically significant for the in vivo part of the study. In the ex vivo part of the study, P<0.01 was considered statistically significant as a correction for multiple comparisons. Statistical analyses were performed using Statistica (Dell, Austin, TX, USA).

**Results**

**In vivo effects of exposure in the pig barn**

**Exposure, symptoms, and lung function**

The mean (range) level of inhalable dust was 6.3 (2.1–17.0) mg/m³ and respirable dust 0.5 (0.32–1.3) mg/m³. At baseline, COPD Assessment Test score mean (range) was 3.3 (0–7) in the controls and 17.7 (7–34) in the COPD group and before in vivo exposure 3.8 (1–11) in the controls and 17.3 (4–34) in the COPD group. Exposure in vivo induced sneezing (P=0.027) and cough (P=0.003) in the controls and headache (P=0.006), fatigue (P=0.016), cough (P=0.039), chest tightness (P=0.002), and breathlessness (P=0.003) in the COPD group. Post-exposure headache (P=0.02), fatigue (P=0.04), chest tightness (P=0.001), and breathlessness (P<0.0001) were more severe in the COPD group than in controls. Body temperature increased by 0.4°C (P=0.001) following exposure in both groups.

Baseline FEV₁ and FVC were lower in subjects with COPD than in controls, and exposure in vivo induced a greater fall in FEV₁ (P<0.0001) and FVC (P<0.0001) in the COPD group than in controls (Figure 2). In the controls, PEF fell from 531 (95% CI 457–604) L/min to 489 (411–566) L/min (7.9%; P=0.001) and from 325 (295–356) L/min to 240 (201–240) L/min (26.2%; P=0.0007) in the COPD group (P=0.0004 between groups).

The methacholine challenge induced chest tightness (P=0.0015) in controls and cough (P=0.049) in the COPD group, with no difference between the groups. All symptoms disappeared within 24 hours after the challenge. Bronchial responsiveness to methacholine was enhanced in COPD subjects compared with controls (P=0.004, Table 1). There was no correlation between FEV₁ after in vivo exposure and bronchial responsiveness to methacholine (Figure 2).

**Cells and mediators following in vivo exposure**

**Sputum**

Sputum-cell concentrations did not differ between the groups at baseline (P=0.15). Exposure in vivo induced increased numbers of sputum cells in COPD subjects (P=0.002) and controls (P<0.001), with no difference between the groups (P=0.88; Figure 3).

Baseline sputum levels of MMP9, TIMP1, IL6, and CXCL8 were higher in COPD subjects than in controls. Concentrations of MMP9, TIMP1, CXCL8, IL6, TNFα, and LTB₄ increased significantly and similarly in both groups (Figure 3). ChAT and AChE expression in sputum neutrophils, monocytes, and lymphocytes did not change after in vivo exposure in either group, and no differences were observed between the groups at baseline or after in vivo exposure (Table 2).

After methacholine provocation, total cell numbers in sputum decreased in the COPD group (P=0.03) and were unaltered in the control group (P=0.61), with no difference between the groups (P=0.19).

**Blood analyses**

At baseline, the COPD group had higher numbers of blood neutrophils (P=0.046) and monocytes (P=0.0014) than the controls (Figure 4). Following in vivo exposure, there was a significant increase in blood neutrophils and monocytes and a significant reduction in lymphocytes in controls (P<0.01 for all). In COPD subjects, blood neutrophils increased after exposure (P=0.01), while monocytes and lymphocytes were unaltered (P≥0.12). Blood-cell reaction to in vivo exposure did not differ significantly between COPD subjects and controls. Blood eosinophils did not differ significantly between controls and COPD subjects at baseline (35 [18–64]×10⁶ cells/L and 21.5 [9–71]×10⁶ cells/L, respectively) or after exposure (29 [17–58]×10⁶ cells/L and 15 [5–26]×10⁶ cells/L, respectively).

Baseline levels of blood MMP9 and MMP9:TIMP1 ratios were higher in COPD subjects than in controls (Figure 4). Exposure in vivo increased blood MMP9 levels and the
MMP9:TIMP1 ratios in both groups, with no significant difference between the groups ($P=0.88$; Figure 4). Baseline blood levels of IL6 and CRP did not differ between the groups and blood IL6 and CRP increased significantly in both groups following exposure in vivo. IL6 increase was greater in controls than in COPD subjects ($P=0.042$; Figure 4) and the CRP increase greater in the COPD group than in controls ($P=0.036$; Figure 4).

In the controls, baseline expression of CXCR1 was lower in COPD subjects (45.4 [35.0–57.0] relative median ($I$) versus 58.7 [43.0–66.0] relative median ($I$) in the COPD group, $P=0.009$).

Table 1 Baseline characteristics of healthy non-smokers (controls) and smokers with COPD

<table>
<thead>
<tr>
<th></th>
<th>Controls, n=15</th>
<th>COPD, n=15</th>
<th>$P$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male</td>
<td>9/6</td>
<td>11/4</td>
<td>0.22</td>
</tr>
<tr>
<td>Age (years), mean, range</td>
<td>60.5 (50–71)</td>
<td>63.3 (53–77)</td>
<td></td>
</tr>
<tr>
<td>Smoking (pack-years), mean, range</td>
<td>42.2 (22–95)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD Assessment Test (points), mean, range</td>
<td>3 (0–7)</td>
<td>18 (7–34)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FEV$_1$ (L), mean (95% CI)</td>
<td>3.20 (2.63–3.78)</td>
<td>1.85 (1.67–2.03)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FEV$_1$ (% predicted), mean (95% CI)</td>
<td>96 (87–104)</td>
<td>67 (61–74)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FVC (L), mean (95% CI)</td>
<td>3.89 (3.25–4.52)</td>
<td>2.84 (2.61–3.07)</td>
<td>0.002</td>
</tr>
<tr>
<td>FVC (% predicted), mean (95% CI)</td>
<td>88 (82–94)</td>
<td>80 (73–86)</td>
<td>0.05</td>
</tr>
<tr>
<td>FEV$_1$/VC or FVC (%), mean (95% CI)</td>
<td>0.81 (0.77–0.85)</td>
<td>0.60 (0.56–0.64)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>PD$_{20}$FEV$_1$ (mg), median (25th–75th percentile)</td>
<td>2.72 (0.59–11.1)</td>
<td>0.30 (0.06–0.66)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

Notes: Lung function was measured 15 minutes after inhalation of 0.4 mg salbutamol. $P$-values refer to between-group comparisons and were calculated by mean of unpaired t-tests or Mann–Whitney U test (the cumulative dose causing a 20% decrease in FEV$_1$ [PD$_{20}$FEV$_1$]).
fluorescence intensity) than in controls (72.7 [61.7–83.8] relative median fluorescence intensity; \( P = 0.014 \)) and in vivo exposure induced relative falls in CXCR1 expression in blood neutrophils compared with COPD subjects (\( P = 0.04 \)). CXCR2 expression in blood neutrophils was similar at baseline in both groups and did not change after in vivo exposure in either group (data not shown). Baseline expression of ChAT and AChE in blood cells did not differ between the groups (Table 2). In vivo exposure decreased ChAT (\( P = 0.02 \)) and AChE (\( P = 0.04 \)) in lymphocytes in controls, but did not alter their expression in other cell types in either group (Table 2).

### Ex vivo stimulation of blood neutrophils

With a few exceptions, no significant differences were found between before and after in vivo exposure or between COPD and controls with regard to the effects of neutrophil stimulation with dust, acetylcholine, and the combination thereof or the effect of the drugs (tiotropium, pirenzepine, solifenacin, neostigmine). Therefore, unless otherwise stated, results of measured outcomes are given for before in vivo exposure.

Dust significantly decreased neutrophil expression of CXCR1 in controls (\( P = 0.0003 \)). In COPD subjects, a similar pattern was observed, but did not reach statistical significance (\( P = 0.015 \)). A similar pattern was observed after in vivo exposure. Dust increased the expression of CXCR2 in both groups (Figure 5A and B). Dust-induced alteration of CXCR1 and CXCR2 expression was not altered by tiotropium (Figure 5A and B), pirenzepine, solifenacin, or neostigmine (data not shown).

Dust induced increased levels of ChAT in neutrophils from controls (\( P < 0.0001 \)) and COPD (\( P = 0.0003 \); Figure 5C) before in vivo exposure and in COPD subjects after in vivo exposure (\( P < 0.001 \)). Before and after in vivo exposure, dust induced significantly increased secretion of TNFα in controls and COPD subjects, with no difference between the groups (\( P \geq 0.2 \)). Dust-induced TNFα release was not altered by tiotropium (Figure 6A) or any other drug (data not shown).

Release of LTB₄ from blood neutrophils was not influenced by dust stimulation (Figure 6B), but decreased after stimulation with acetylcholine in controls before and in COPD

---

**Figure 3** Sputum analyses before and after in vivo exposure in COPD subjects and controls.

**Notes:** Horizontal lines indicate comparisons between pre- and postexposure values. Double arrows indicate comparisons between baseline (preexposure) values. Median values and 25th–75th percentiles indicated by bars and vertical lines.

---

For personal use only.

**Dovepress**

Cholinergic mechanisms in an organic dust model

International Journal of COPD 2018:13

Submit your manuscript | www.dovepress.com

Dovepress

Cholinergic mechanisms in an organic dust model

International Journal of COPD 2018:13

Submit your manuscript | www.dovepress.com

Dovepress
Table 2 Expression of acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) in Healthy non-smokers (controls) and Smokers with COPD before and after in vivo exposure in a pig barn.

<table>
<thead>
<tr>
<th></th>
<th>Before in vivo exposure (baseline)</th>
<th>After in vivo exposure</th>
<th>P-value</th>
<th>Before in vivo exposure (baseline)</th>
<th>After in vivo exposure</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sputum</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>AChE 2.04 (1.70–2.66)</td>
<td>1.69 (1.29–1.91)</td>
<td>0.60</td>
<td>2.29 (1.79–2.84)</td>
<td>2.58 (2.42–3.05)</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>ChAT 1.80 (1.58–2.95)</td>
<td>1.97 (1.56–2.40)</td>
<td>1.00</td>
<td>2.36 (1.69–2.75)</td>
<td>2.27 (2.01–2.76)</td>
<td>1.00</td>
</tr>
<tr>
<td>Monocytes</td>
<td>AChE 2.09 (1.45–3.08)</td>
<td>1.91 (1.33–2.61)</td>
<td>0.58</td>
<td>2.25 (2.05–2.62)</td>
<td>2.65 (2.29–2.93)</td>
<td>0.10</td>
</tr>
<tr>
<td></td>
<td>ChAT 2.53 (1.51–3.45)</td>
<td>1.63 (1.18–1.95)</td>
<td>0.096</td>
<td>1.84 (1.69–2.43)</td>
<td>1.64 (1.37–3.05)</td>
<td>1.00</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>AChE 2.24 (1.40–2.68)</td>
<td>1.41 (1.15–1.60)</td>
<td>0.27</td>
<td>2.38 (1.99–3.78)</td>
<td>2.47 (2.06–3.08)</td>
<td>0.77</td>
</tr>
<tr>
<td></td>
<td>ChAT 2.12 (1.71–2.77)</td>
<td>1.46 (1.11–1.81)</td>
<td>0.58</td>
<td>1.81 (1.54–3.17)</td>
<td>1.47 (1.40–1.93)</td>
<td>0.27</td>
</tr>
<tr>
<td><strong>Blood</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>AChE 2.27 (1.94–3.07)</td>
<td>1.91 (1.54–2.44)</td>
<td>0.30</td>
<td>2.12 (1.75–2.50)</td>
<td>1.86 (1.73–2.58)</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>ChAT 2.17 (1.78–3.24)</td>
<td>2.18 (1.87–2.54)</td>
<td>1.00</td>
<td>2.17 (1.70–2.55)</td>
<td>2.18 (1.58–2.57)</td>
<td>0.30</td>
</tr>
<tr>
<td>Monocytes</td>
<td>AChE 2.93 (2.63–3.40)</td>
<td>2.85 (2.50–3.75)</td>
<td>0.58</td>
<td>3.47 (2.93–4.20)</td>
<td>2.94 (2.44–3.71)</td>
<td>0.18</td>
</tr>
<tr>
<td></td>
<td>ChAT 1.71 (1.53–2.40)</td>
<td>1.92 (1.83–2.36)</td>
<td>0.30</td>
<td>2.08 (1.60–2.39)</td>
<td>1.96 (1.50–2.30)</td>
<td>0.79</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>AChE 3.00 (2.50–3.13)</td>
<td>1.85 (1.46–2.95)</td>
<td>0.04</td>
<td>2.83 (2.44–3.38)</td>
<td>2.67 (2.00–3.37)</td>
<td>0.79</td>
</tr>
<tr>
<td></td>
<td>ChAT 1.65 (1.44–1.80)</td>
<td>1.25 (1.08–1.54)</td>
<td>0.02</td>
<td>1.74 (1.38–2.00)</td>
<td>1.67 (1.35–2.10)</td>
<td>0.76</td>
</tr>
</tbody>
</table>

Notes: Expression of AChE and ChAT on neutrophils, monocytes, and lymphocytes in sputum and blood before and after in vivo exposure (2 hours of exposure in a pig barn) in controls (healthy non-smokers) and smokers with COPD. Enzyme expression assessed by flow cytometry and presented as relative median fluorescence intensity. Values expressed as mean (95% CI).

Figure 4 Blood analyses before and after in vivo exposure in a pig barn in COPD subjects and controls. Notes: Horizontal lines indicate comparisons between pre- and post-exposure values. Double arrows indicate comparisons between baseline (pre-exposure) values. Horizontal brackets indicate comparisons between exposure-induced changes between the groups. Median values and 25th–75th percentiles indicated by bars and vertical lines.
Figure 5 CXCR1, CXCR2 and ChaT expression.

Notes: Isolated blood neutrophils stimulated ex vivo with organic dust and the effect of tiotropium (Tio) in healthy controls and patients with COPD. Neutrophils were collected before and 7 hours after in vivo exposure in a pig barn. As the results were not significantly influenced by in vivo exposure in either group, only data before in vivo exposure are included in the figure. Data presented as relative median fluorescence intensity (rMFI) and mean (SEM). (A) CXCR1 expression on neutrophils was decreased by dust in controls ($P=0.0003$), but not in the COPD group ($P=0.015$). (B) Dust increased the expression of CXCR2 in both groups ($P=0.002$). Tio did not significantly influence CXCR1 or CXCR2 expression before (A, B) or after in vivo exposure (data not shown) in either group. (C) Dust induced increased expression of choline acetyltransferase (ChaT) on neutrophils in controls ($P<0.0001$) and COPD ($P=0.0003$) before in vivo exposure. Similar findings were obtained after in vivo exposure (data not shown). There was no difference between the groups, nor did Tio alter the outcome.

Discussion

Exposure to organic dust in a pig barn (in vivo exposure) induced more serious symptoms in subjects with COPD than in healthy non-smokers. The increase in symptoms was similar to what COPD patients experience during acute exacerbations and was associated with substantial lung function impairment (assessed by FEV$_1$, FVC, and PEF) in the COPD group. It has previously been shown that exposure in a pig barn does not alter bronchial responsiveness to an indirect stimulus, such as eucapnic hyperventilation, but induces a powerful increase in bronchial responsiveness to a cholinergic stimulus, such as methacholine, which is independent of baseline lung function assessed as FEV$_1$. The present data showed that patients with COPD were more sensitive to the bronchoconstrictive effect of in vivo exposure than the controls, which was likely a result of lower baseline lung function. Intriguingly, this deterioration in lung function induced by in vivo exposure did not correlate with responsiveness to methacholine assessed as PD$_{20}$FEV$_1$, implying that lung-function alteration following exposure in a pig barn was not related to bronchial responsiveness.

Exposure in a pig barn induces an intense airway and systemic inflammation in healthy subjects, and in the present study it was demonstrated that the inflammatory response to exposure in a pig barn was similar in healthy
Figure 6 (A) Before in vivo exposure, the release of TNFα from isolated blood neutrophils increased following ex vivo stimulation with dust in controls ($P=0.0002$) and COPD ($P=0.0014$). A similar increase was observed in controls ($P=0.0069$) and COPD ($P=0.0014$) after in vivo exposure (data not shown). There was no difference between the groups ($P=0.20$). Dust-induced TNFα release was not significantly altered by tiotropium (Tio). (B) Dust by itself did not influence LTB4 release in either group before (and after, data not shown) in vivo exposure. (C, D) Acetylcholine (Ach; 100 µM) induced a significant decrease in LTB4 release from neutrophils before in vivo exposure (C) in controls ($P=0.0017$) and after in vivo exposure (D) in the COPD group ($P=0.0002$). Tio did not significantly alter the response induced by Ach. (E) Before in vivo exposure, dust increased LTB4 release in the presence of pirenzepine in controls ($P=0.0036$) and COPD ($P=0.0092$). Similar findings were observed after in vivo exposure ($P=0.0022$; data not shown). The combination of dust and neostigmine induced increased LTB4 release in controls ($P=0.0008$) and COPD ($P=0.0003$) before in vivo exposure. Similar findings were observed after in vivo exposure ($P=0.0021$; data not shown). Data presented as mean (SEM).

non-smokers and smokers with COPD. At baseline, inflammatory markers in sputum and blood were elevated in subjects with COPD compared with the controls. Following exposure, however, similar alterations in sputum inflammatory cells, pro-inflammatory cytokines (IL6, TNFα), mediators involved in cell migration (CXCL8, LTB4), and mediators involved in tissue degradation (MMP9, TIMP1) were observed in both groups. The inflammatory characteristics induced by exposure in a pig barn with increased sputum levels of IL6, TNFα, CXCL8, and LTB4 thus very much resembled what is observed in acute exacerbations in COPD.$^{12,13,28–34}$

Both MMP9 and TIMP1 in sputum were significantly higher before in vivo exposure in the COPD group, indicating
ongoing degradation of the extracellular matrix, which is a
key feature during airway remodeling. However, exposure
in vivo induced an increase in sputum levels of both MMP9
and its specific inhibitor TIMP1 in both groups and an
increase in the MMP9:TIMP1 ratio in COPD patients. This
is, in part, in contrast to the finding in acute exacerbations
of COPD in which sputum levels of MMP9 increase,23,24
whereas the concentration of TIMP1 decreases, yielding
an increased MMP9:TIMP1 ratio.33 Previous findings are,
however, not unequivocal, as other results have indicated an
association between low MMP9:TIMP1 ratio and impaired
lung function (FEV1) in patients with COPD and/or chronic
bronchitis.35 Blood level of MMP9 increased as a result of
in vivo exposure, whereas blood concentration of TIMP1
remained unaltered, leading to an increased MMP9:TIMP1
ratio in blood in both controls and COPD subjects. Also in
blood, both MMP9 and TIMP1 were significantly increased at
baseline in the COPD group, as previously demonstrated.36

As anticholinergic drugs constitute first-line therapy in
COPD, it cannot be excluded that these drugs may also have
an influence on nonneuronal cholinergic mechanisms operat-
ing in inflammatory cells. One of our aims was to explore
whether the non-neuronal cholinergic system is activated
by exposure to organic dust as a simulation of an exacerb-
ation and whether this activation is altered in COPD patients
compared with healthy non-smokers. With the exception of
a slight downregulation of ChAT and AChE in circulating
lymphocytes in controls, exposure in the pig barn did not
alter cellular expression of enzymes (ChAT and AChE) in
sputum or blood. The expression of AChE in neutrophils and
monocytes in sputum did not change significantly following
in vivo exposure, but AChE expression was regulated in
opposite directions in COPD subjects and controls, which
resulted in a tendency toward a difference between the groups
(P=0.05 and 0.07). In addition, ex vivo data strongly support
the involvement of cholinergic mechanisms in the response
to dust, as ChAT expression on neutrophils clearly increased
following dust exposure in both groups. The significance of
this finding is difficult to interpret, as knowledge about the
importance of acetylcholine turnover in inflammatory
cells is sparse.16 Our results suggest that non-neuronal
cholinergic responses – assessed as the capacity to catalyze
the formation and breakdown of acetylcholine in inflamma-
tory cells – are activated following exposure to dust in vivo
and ex vivo. These responses do not, however, seem to be
altered in COPD. We conclude that exposure to a strong
pro-inflammatory stimulus (dust) that elicits an inflam-
matory response similar to what is observed during acute
exacerbations in COPD may be associated with an alteration
in cholinergic activity in inflammatory cells in the airway
and in the circulation.

The number of neutrophils in blood was significantly
increased in COPD patients, indicating a systemic inflam-
mation. Exposure induced a greater CRP increase in blood
but a lower increase in circulating IL6 in the COPD group
compared with the healthy non-smokers. Therefore, even
if patients with COPD had signs of systemic inflammation
with somewhat higher levels of circulating neutrophils, the
response to an acute pro-inflammatory stimulus seemed to
be downregulated. It has previously been shown that con-
centrations of acute-phase proteins, eg, CRP, are increased
at 24 hours but not 6 hours after exposure in a swine-con-
finement building,2 which is in agreement with the present
results in the healthy non-smokers. As IL6 constitutes an
endogenous stimulus for hepatic CRP production27 it would
be reasonable to assume that the more pronounced increase
in circulating IL6 in the controls would be associated with a
greater CRP increase in this group than in the COPD group.
The finding of the opposite, ie, augmented CRP increase in
the COPD group, indicates that the time kinetics for acute-
phase protein production and the interaction between IL6
and acute-phase protein synthesis may be altered in COPD
subjects compared with healthy non-smokers.

We focused our ex vivo studies on neutrophils, as these
cells are of importance in COPD and dominate the response
to pig-barn exposure in vivo. Therefore, in order to find out
whether or not 2 hours of exposure in a pig barn alters cellular
responsiveness to dust and cholinergic stimuli, we conducted
ex vivo stimulation of neutrophils isolated from peripheral
blood before and 7 hours after beginning the exposure in
the pig barn. At baseline, the expression of CXCR1 (but not
CXCR2) on blood neutrophils was decreased in the COPD
group compared with controls. In vivo exposure did not alter
CXCR1 expression in blood neutrophils in either group, but
slightly increased expression was found in the COPD group,
which differed significantly from controls. These findings
were corroborated by the ex vivo findings, with more marked
downregulation of CXCR1 expression in neutrophils from
controls than from patients with COPD. We thus conclude that
regulation of CXCR1, but not CXCR2, on neutrophils differs
between healthy non-smokers and smokers with COPD.

Both CXCR1 and CXCR2 enhance neutrophilic chemot-
actic activity.38 CXCR1 binds to CXCL6 and CXCL8, and
is – apart from being important for neutrophil chemotaxis –
also of importance for neutrophil activation.39 Stimulation
of CXCR2 leads to neutrophil chemotaxis through binding
to a number of chemokines, such as CXCL1–CXCL3, CXCL5, CXCL6, and CXCL8. While lipopolysaccharides exhibit neutrophil chemotaxis by activating both CXCR1 and CXCR2, it is intriguing that ex vivo activation of isolated neutrophils in the present study reduced CXCR1 and enhanced CXCR2 expression. The finding of increased sputum levels of CXCL8 induced by in vivo exposure is in agreement with previous research. The source of CXCL8 following exposure to dust from a pig barn has previously been shown to be macrophages and airway epithelial cells, and the present results show that neutrophils do not contribute to CXCL8 release induced by exposure to the dust. The explanation of this dualistic effect on CXCR1 and CXCR2 is not clear, but it is reasonable to assume that one of the mechanisms behind the powerful neutrophil chemotaxis induced by exposure in a pig barn is mediated through interaction between CXCL8 chemokines and CXCR2.

Also LTB₄ is likely to be an important neutrophil chemoattractant, and is released upon stimulation with dust from a pig barn. Dust had no clear effect on LTB₄ release from neutrophils, whereas acetylcholine reduced LTB₄ release in both groups and no further effect of tiotropium was observed. This is in contrast to a previous study, in which acetylcholine did not alter LTB₄ release from sputum cells. In addition, in that study an unselective M-receptor blocker (oxitropium bromide) prevented LTB₄ release. The most likely explanation for these discrepancies is that isolated neutrophils were used in the present study and “sputum cells” in the study by Profita et al, leading to the conclusion that cells other than neutrophils were probably responsible for the outcome in that study.

Stimulation of isolated neutrophils with dust in the presence of neostigmine, an AChE inhibitor, induced a two- to fourfold increase in LTB₄ release. It was also shown that dust induced increased expression of ChAT in neutrophils, which likely augment the effect of neostigmine. These findings indicate that endogenous but not exogenous acetylcholine may activate LTB₄ release. In addition, blocking the M₁ receptor with pirenzepine entailed a dust-induced doubling of LTB₄ release from neutrophils. The explanation for this is not clear. There are findings from animal studies indicating that activation of the M₁ receptor may exhibit anti-inflammatory effects, e.g., by suppressing TNFα release, an effect that seemed to be mediated through neuronal cholinergic mechanisms. There are data from animal experiments supporting vagal stimulation inhibiting TNFα release and leukocyte accumulation in endotoxemia, an effect that is attenuated by nicotinic receptor (α7nAChR) antagonism. We do not know of any studies on M₁-receptor function in neutrophils. From the present data, it could however be hypothesized that blocking the M₁ receptor on neutrophils has pro-inflammatory effects by constituting a stimulus for LTB₄ release, thereby being a further chemoattractant for neutrophils.

Occupational exposure in pig farms includes gases and organic dust containing particles. Apart from particles from hay, grasses, pollen, pig epithelial cells, and feedstuffs, the dust contains high amounts of Gram-positive and Gram-negative bacteria and fungi, as well as high levels of airborne endotoxins and peptidoglycans. It is not known what components are responsible for the pro-inflammatory potency of dust in a pig farm, but it is most likely that the high microbial content plays a major role. Neutrophils possess M₁, M₂, and M₅ receptors, of which M₁ receptors are the most abundant. There are indications that cholinergic regulation of airway inflammation is mediated mainly through activation of M₁ receptors and that M₁ receptors may be less involved in this respect. It has previously been demonstrated that anticholinergic agents inhibit neutrophil chemotaxis through influencing chemokine release from structural cells and macrophages. The role of the M receptors located on neutrophils is not fully understood. In the present study, we were not able to show that acetylcholine had any influence on most mediator release from neutrophils. As such, release of MMP9, a profibrotic factor (TGFβ), chemokines regulating leukocyte migration (CXCL8, CXCL10), CXCL8 receptors (CXCR1, CXCR2), or enzymes regulating acetylcholine (ChAT, AChE) of neutrophils from healthy non-smokers and patients with COPD were not influenced by acetylcholine per se, and acetylcholine did not alter the response to dust stimulation. Possibly apart from LTB₄ release, it seems likely that neutrophils do not function as important target cells for cholinergic stimuli as far as the measured mediators in the present study are concerned.

**Conclusion**

Dust from pig barns constitutes a very potent pro-inflammatory stimulus, both in vivo and ex vivo. Certain inflammatory markers in sputum and blood were enhanced at baseline in COPD subjects, but airway and systemic inflammatory responses to in vivo exposure did not differ substantially between the groups, despite the finding that in vivo exposure induced more severe symptoms and more severe lung-function deterioration in smokers with COPD than healthy subjects.
non-smokers. Ex vivo stimulation of blood neutrophils did not reveal differences in neutrophil responses to dust before or after in vivo exposure or between controls and COPD subjects. Ex vivo exposure to dust induced cholinergic activation, assessed as increased expression of ChAT in neutrophils, but in conclusion cholinergic stimulation seems to constitute a weak pro-inflammatory stimulus in neutrophils.

**Acknowledgment**

The authors wish to thank Marianne Olsson for excellent technical assistance and for delivering subjects to the pig barns on the exposure days and the Swedish Heart-Lung Foundation.

**Author contributions**

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


